Cargando…
Should statins be considered for the management of mucormycosis in COVID-19?
Autores principales: | Chatterjee, Subhankar, Vardhan, Bhagya, Singh, Deepa Kumari, Maitra, Abhishek, Ojha, Umesh Kumar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Diabetes India. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178941/ https://www.ncbi.nlm.nih.gov/pubmed/34186353 http://dx.doi.org/10.1016/j.dsx.2021.05.035 |
Ejemplares similares
-
Myocardial infarction after COVID-19 vaccination-casual or causal?
por: Chatterjee, Subhankar, et al.
Publicado: (2021) -
An epidemic of iatrogenic Cushing's syndrome in anticipation in post-COVID era
por: Chatterjee, Subhankar, et al.
Publicado: (2022) -
COVID-19, steroids, and mucormycosis: What an ophthalmologist should know
por: Tandon, Abhishek, et al.
Publicado: (2021) -
Post-COVID-19 pulmonary cavitation and tension pneumothorax in a non-ventilated patient
por: Vardhan, Bhagya, et al.
Publicado: (2022) -
Should depressive patients undergo a regular diabetes screening test?
por: Ghosh, Subhasish, et al.
Publicado: (2013)